Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor

By Maekawa Ryuji   Maki Hideo   Wada Tohru   Yoshida Hiroshi   Nishida-Nishimoto Kazuyo   Okamoto Hiroyuki   Matsumoto Yayoi   Tsuzuki Hiroshige   Yoshioka Takayuki  

Clinical and Experimental Metastasis, Vol. 18, Iss. 1, 2000-01 ,pp. : 61-66

Springer Publishing Company

Access to resources Recommend Favorite

Anti-invasive Effect of MMI-166, a New Selective Matrix Metalloproteinase Inhibitor, in Cervical Carcinoma Cell Lines

By Iwasaki M.   Nishikawa A.   Fujimoto T.   Akutagawa N.   Manase K.   Endo T.   Yoshida K.   Maekawa R.   Yoshioka T.   Kudo R.  

Gynecologic Oncology, Vol. 85, Iss. 1, 2002-04 ,pp. : 103-107

Elsevier

Access to resources Recommend Favorite

Anti-metastatic and anti-angiogenic activities of a new matrix metalloproteinase inhibitor, TN-6b

By Lee S.J.   Sakurai H.   Oshima K.   Kim S.H.   Saiki I.  

European Journal of Cancer, Vol. 39, Iss. 11, 2003-07 ,pp. : 1632-1641

Elsevier

Access to resources Recommend Favorite

Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2

By                    

Oncology Reports, Vol. 28, Iss. 5, 2012-01 ,pp. : 1799-1807

Spandidos Publications

Access to resources Recommend Favorite

The in vitro and in vivo anti-metastatic efficacy of oxythiamine and the possible mechanisms of action

By Yang Chih-Min   Liu Yi-Zih   Liao Jiunn-Wang   Hu Miao-Lin  

Clinical and Experimental Metastasis, Vol. 27, Iss. 5, 2010-05 ,pp. : 341-349

Springer Publishing Company

Access to resources Recommend Favorite